Insmed (INSM) Q3 2026 Earnings
As seen on the 24/7 Wall St. homepage on October 29, 2026.
Q3 2026
EPS
-$0.46
est -$0.38
-21.5%
Revenue
$524M
est $499M
+5.0%
BRINSUPRI's US launch pulled in $400.1 million in segment revenue, and Insmed raised the low end of full-year guidance for the drug to $1.35 billion. The GAAP loss missed expectations, but management now sees cash flow positivity in 2027 without raising capital.
Mentioned: INSM
Sponsored